State of Alaska Department of Revenue Sells 145 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
State of Alaska Department of Revenue reduced its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 1.3% ...
Deutsche Bank Aktiengesellschaft Initiates Coverage on Sarepta Therapeutics (NASDAQ:SRPT)
Equities research analysts at Deutsche Bank Aktiengesellschaft assumed coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) in a research report issued on Tuesday, MarketBeat ...
Managed Healthcare Executive1d
Sarepta Announces Positive Results for Elevidys, Gene Therapy for Duchenne
Results show improved functional outcomes for people with Duchenne muscular dystrophy who are ambulatory. Elevidys, which is ...
Insider Monkey14d
Jim Cramer Says ‘I Think Sarepta Therapeutics, Inc. (SRPT) Is A Speculative Situation Where They Have Great Science’
In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other stocks. Jim Cramer, the host of Mad Money, recently expressed his concerns ...
Roche reports positive topline outcomes from DMD treatment trial
Roche has reported positive topline outcomes from the second year of the multinational Phase III EMBARK trial of Elevidys (delandistrogene moxeparvovec) as a gene therapy for treating Duchenne ...
Business Insider17d
Sarepta Therapeutics’ Strong Market Position and Elevidys’ Promising Prospects Drive Buy Rating
In a report released yesterday, Kostas Biliouris from BMO Capital maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price target of $200.00. Kostas Biliouris has ...
Pharmabiz17d
Roche announces positive results from EMBARK phase III study of Elevidys in ambulatory individuals with DMD
Roche announces positive results from EMBARK phase III study of Elevidys in ambulatory individuals with DMD: Basel Tuesday, January 28, 2025, 11:00 Hrs [IST] Roche announced posit ...
Business Insider17d
Sarepta Therapeutics: Buy Rating Affirmed on Positive EMBARK Study Results and Strong Financial Outlook
Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Buy rating on Sarepta Therapeutics (SRPT – Research Report). The associated price target remains the same with $217.00.
PMLiVE17d
Roche/Sarepta announce two-year results for Duchenne muscular dystrophy gene therapy
Roche and Sarepta Therapeutics have shared positive top-line results ... condition caused by a change or mutation in the gene that encodes instructions for dystrophin, which is required to strengthen ...